CS on Sun Pharma
Ilumya's success crucial given high opex
Already 1 yr since Ilumya launch & ramp-up still weak
Lower Ilumya est further for FY21 to $55m (from $80 m) & cut FY21E EPS to 19.6, now 15% lower than consensus We Cut TP to Rs 450 from Rs 470